Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADfind
2025-521833-97-00Phase 4Authorised
- Sponsor
- University of Michigan
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 4, open-label trial of lebrikizumab in atopic dermatitis (AD) (2 arms), sponsored by University of Michigan. Primary endpoint: Degree of normalization of transcriptomic and epigenetic profile in skin biopsies over time. Planned start Aug 2025; status: authorised.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2025-521833-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521833-97-00.